



LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

PTO FORM 1449 - Supplemental

ATTY. DOCKET NO.	APPLICATION NO.
03678.0073.DVUS04	10/682,545
APPLICANT	
Ward M. Peterson et al.	
FILING DATE	GROUP
October 8, 2003	1623

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	1.						
	2.						
	3.						

FOREIGN PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
M	4.	WO 98/34593	13.08.98	PCT	A61K	9/00	Y	
	5.							
	6.							

OTHER REFERENCES

(Including Author, Title, Date, Pertinent Pages, Etc.)

	7.	
	8.	
	9.	
	10.	
	11.	
	12.	
	13.	
	14.	
	15.	
	16.	
	17.	

deChane

10/15/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i>	ATTY. DOCKET NO.	APPLICATION NO.
	03678.0073.DVUS04	10/682,545
APPLICANT Ward M. Peterson et al.		
FILING DATE	GROUP	
October 8, 2003	1623	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>AM</i>	1.	US 6,319,908 B1	11/20/01	Yerxa <i>et al.</i>	514	51	07/24/98
	2.	US 6,548,658 B2	04/15/03	Yerxa	536	26.22	11/20/01
	3.	US 6,555,675 B2	04/29/03	Rideout <i>et al.</i>	536	25.6	03/23/01
	4.	US 6,596,725 B2	07/22/03	Peterson <i>et al.</i>	514	256	01/30/01
	5.	US 6,673,779 B2	01/06/04	Jacobus <i>et al.</i>	514	51	06/05/02
<i>AM</i>	6.	US 6,696,425 B2	02/24/04	Yerxa <i>et al.</i>	514	47	12/19/01

FOREIGN PATENT DOCUMENTS


OTHER REFERENCES

(Including Author, Title, Date, Pertinent Pages, Etc.)

McNamee

10/15/05

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

 <p>LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)</p> <p>USPTO FORM 1449</p> <p>JUL 16 2004</p>		ATTY. DOCKET NO.	APPLICATION NO.
		03678.0073.DVUS04	10/682,545
		APPLICANT	
		Peterson et al.	
FILING DATE	GROUP		
Oct. 8, 2003	1623		

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
M	1.*	6,040,297	03/21/00	De Flora	514	047	01/14/97
	2.*	6,258,374	07/21/01	Freiss et al.	424	436	09/03/98
	3.*	6,348,589	02/2002	Pendergast et al.	536	25.6	02/06/98
	4.*	6,323,187	11/2001	Yerxa et al.	514	51	05/21/99
	5.*	6,277,855	08/2001	Yerxa	514	256	04/21/00
	6.*	6,458,946	10/01/02	Maeda et al.	536	26.21	10/01/99
M	7.*	US2002/0156269 A1	10/24/02	Maeda et al.	536	26.21	04/12/02

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
M	8.*	EP 1 043 329 B1	08/28/02	EP	C07H	19/10	X	
	9.*	EP 1 191 032 A1	03/27/02	EP	C07H	19/10	X	
	10.*	WO 98/34942	08/13/98	WO	5	—		
	11.*	WO 00/30629	06/02/00	WO	—	—		
M	12.*	WO 01/87913	11/22/01	WO	—	—		

OTHER REFERENCES
(Including Author, Title, Date, Pertinent Pages, Etc.)

M	13.*	Blaug, et al., "P2Y2 receptor agonists induce prolonged calcium, membrane voltage, conductance and fluid absorption increases in bovine RPE," <i>IOVS</i> , 41(4):S136 (2000) XP001088187
	14.*	Burnstock, et al., "P2 purinergic receptors: Modulation of cell function and therapeutic potential," <i>Journal of Pharmacology and Experimental Therapeutics</i> 295(3) 862-869 (2000) XP002208652
	15.*	Ferris, et al., "Oligomerization reactions of deoxyribonucleotides on montmorillonite clay: the effect of mononucleotide structure on phosphodiester bond formation," <i>Origins Life Evol. Biosphere</i> , 19(6):609-619 (1989) XP001085277
	16.*	Maminishkis, et al., "Purinoceptor agonists increase fluid clearance out of subretinal space (SRS) blebs in vivo," <i>IOVS</i> , 41(4):S136 (2000) XP001083820
	17.	Maminishkis, et al., "The P2Y ₂ Receptor Agonist INS37217 Stimulates RPE Fluid Transport In Vitro and Retinal Reattachment in Rat," <i>IOVS</i> , 43(11): 3555-3566 (2002).
M	18.	Meyer, et al., "Effect of INS37217, a P2Y ₂ Receptor Agonist, on Experimental Retinal Detachment and Electroretinogram in Adult Rabbits," <i>IOVS</i> , 43(11): 3567-3574 (2002).

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT <small>(Use several sheets if necessary)</small>		ATTY. DOCKET NO.	APPLICATION NO.
		03678.0073.DVUS04	10/682,545
		APPLICANT	
		Peterson et al.	
		FILING DATE	GROUP
		Oct. 8, 2003	1623

<i>M</i>	19.	Nour, et al., "P2Y ₂ Receptor Agonist INS37217 Enhances Functional Recovery After Detachment Caused by Subretinal Injection in Normal and <i>rds</i> Mice," IOVS, 44(10): 4505-4514 (2003).
	20.*	Peterson, et al., "Extracellular ATP activates calcium signaling, ion, and fluid transport in retinal pigment epithelium," <i>Journal of Neuroscience</i> , 17(7):2324-2337 (1997) XP001087693
	21.*	Sillero, et al., (2',3'-Dideoxynucleoside triphosphates (ddNTP) and di-2',3'-dideoxynucleoside tetraphosphates (ddNp4ddN) behave differently to the corresponding NTP and NP4N counterparts as substrates of firefly luciferase, and dinucleoside tetraphosphatase and phosphodiesterases," <i>Biochimica et Biophysica Acta</i> 1334(2-3):191-199 (1997) XP002208651
	22.	Takahasi, et al., "Effect of Nucleotide P2Y ₂ Receptor Agonists on Outward Active Transport of Fluorescein Across Normal Blood-retina Barrier in Rabbit," <i>Experimental Eye Research</i> 78:103-108, (2004).
	23.*	Theolclitou, et al., "Characterization of stress protein LysU. Enzyme synthesis of diadenosine 5',5"-P ₁ ,P ₄ -tetraphosphate (Ap4A) analogs by LysU," <i>J. Chem. Soc., Perkins Trans. 1</i> (16):2009-2019 (1996) XP00108769
<i>M</i>	24.*	Williams, M., "P2 Receptors as drug discovery targets," <i>Am. Chem. Soc. 220th, Medi-185</i> (2000) XP001085299
	25.*	Zhavid, et al., "Dicytidine-5'-pyrophosphates with antivirus activity," XP002208653 <i>Not Considered</i> <i>date not provided</i>

M

10/15/05

M

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Spells

DIG-specific signal was detected using a chromophore reaction against the alkaline phosphatase, yielding purple/black staining. The tissues were also counterstained with nuclear fast red. The control sense probe (right) shows no specific labeling. Labeling with the anti-sense probe showed P2Y₂ receptor mRNA localization in scattered nuclei in the ganglion cell and inner nuclear layers and through the inner segment layer of photoreceptors. Strong labeling throughout the RPE was also detected, and in endothelial cells of the choroidal blood vessels.

Example 2. Effects of Synthetic P2Y₂ Agonist UP₄dC on Cloned Human P2Y₂ Receptors

The dinucleotide, [P¹-(uridine 5')-P⁴-(2'-deoxycytidine 5')tetraphosphate tetrasodium salt](UP₄dC) INS37217, was tested for its activity (potency, efficacy, and selectivity) at cloned human P2Y receptor subtypes, which were stably expressed in 1321N1 astrocytoma cells. Activity was assessed using two *in vitro* indices of cell activation: 1) mobilization of intracellular calcium stores, and 2) accumulation of [³H]-inositol phosphates ([³H]-IP). UP₄dC was evaluated for activity in both assays against cells expressing the P2Y₁, P2Y₂, P2Y₄, or P2Y₆ receptors.

UTP and UP₄dC induced mobilization of cytosolic calcium in 1321N1 astrocytoma cells expressing human P2Y₂ (Figure 2) receptors with EC₅₀ values of 0.22 μM and 0.8 μM, respectively. The calcium response to 100 μM UP₄dC was 100% of the maximal response to UTP at P2Y₂ receptors. In conclusion, UP₄dC is a full agonist for calcium mobilization at P2Y₂ receptors compared to UTP.

UTP and UP₄dC stimulated [³H]-IP accumulation in 1321N1 cells expressing human P2Y₂ (Figure 3) receptors with an EC₅₀ values of 1.1 and 2.2 μM, respectively. The inositol phosphate response to 100 μM UP₄dC was approximately that of the maximal response to UTP. In conclusion, UP₄dC is a full agonist for inositol phosphate release at P2Y₂ receptors compared to UTP in the test system.

Example 3. UP₄dC Stimulates Fluid Absorption in Freshly Isolated RPE Monolayers

Fluid transport across freshly isolated, intact bovine and human fetal RPE monolayers was studied using a modified capacitance probe technique (Frambach, *et al.*, *Biophys. J.* 47(4):547-52 (1985); Hughes, *et al.*, *J Gen. Physiol.* 83(6):875-99 (1984)).

The RPE was mounted vertically in a modified Ussing chamber such that apical and